In a regulatory filing made yesterday, the company stated that the Agence nationale de s'curit' du m'dicament et des produits de sant' (ANSM), France, conducted a good manufacturing practices (GMP) inspection of Cenexi's Fontenay manufacturing facility (material subsidiary of Gland Pharma) between 9 to 19 of December 2024. The said inspection was concluded, and the facility received an official notification on 24 December 2024, citing ten observations. Cenexi is committed to working closely with the ANSM to address the observations,' Gland Pharma stated. Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. On a consolidated basis, the firm's net profit declined 15.74% to Rs 163.53 crore despite a 2.36% increase in revenue from operations to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24. The scrip was up 0.62% to currently trade at Rs 1791 on the BSE. Powered by Capital Market - Live

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vitamin K1 Injectable Emulsion USP, 10 mg/mL, of Hospira, Inc. The approved drug is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity. The pharma company expects to launch this Product through its marketing partners in the near future. According to IQVIA, the product had US sales of approximately $15 million for the twelve months ending September 2024. Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. On a consolidated basis, the firm's net profit declined 15.74% to Rs 163.53 crore despite a 2.36% increase in revenue from operations to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vitamin K1 Injectable Emulsion USP, 10 mg/mL, of Hospira, Inc. This Product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity. The Company expects to launch this Product through its marketing partners in the near future. According to IQVIA, the product had US sales of approximately USD 15 million for the twelve months ending September 2024. Powered by Capital Market - Live

Gland Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 1809.85, up 1.67% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 24428.3. The Sensex is at 80776.82, up 0.66%. Gland Pharma Ltd has added around 12.35% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has added around 0.61% in last one month and is currently quoting at 22450.2, up 0.22% on the day. The volume in the stock stood at 1.11 lakh shares today, compared to the daily average of 4.86 lakh shares in last one month.The PE of the stock is 26.58 based on TTM earnings ending September 24.Powered by Capital Market - Live

The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan, Latanoprost Ophthalmic Solution held by UPJOHN US 2 LLC. This product is used for the treatment of high eye pressure/intraocular pressure (IOP) in patients with openangle glaucoma or ocular hypertension. The drug maker expects to launch this product through its marketing partners in FY25. According to IQVIA, the product had US sales of approximately $111.6 million for the twelve months ending December 2023. Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. On a consolidated basis, the firm's net profit declined 15.74% to Rs 163.53 crore despite a 2.36% increase in revenue from operations to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

Chemplast Sanmar Ltd, Hatsun Agro Product Ltd, ABB India Ltd, Bata India Ltd are among the other stocks to see a surge in volumes on BSE today, 05 November 2024.Gland Pharma Ltd saw volume of 47247 shares by 10:47 IST on BSE, a 10.69 fold spurt over two-week average daily volume of 4421 shares. The stock increased 9.75% to Rs.1,766.80. Volumes stood at 6858 shares in the last session.Chemplast Sanmar Ltd recorded volume of 36259 shares by 10:47 IST on BSE, a 5.59 times surge over two-week average daily volume of 6484 shares. The stock gained 4.70% to Rs.497.00. Volumes stood at 7142 shares in the last session.Hatsun Agro Product Ltd witnessed volume of 12872 shares by 10:47 IST on BSE, a 4.76 times surge over two-week average daily volume of 2704 shares. The stock increased 9.17% to Rs.1,160.15. Volumes stood at 9414 shares in the last session.ABB India Ltd recorded volume of 37866 shares by 10:47 IST on BSE, a 4.45 times surge over two-week average daily volume of 8510 shares. The stock lost 3.97% to Rs.7,069.90. Volumes stood at 9507 shares in the last session.Bata India Ltd notched up volume of 43257 shares by 10:47 IST on BSE, a 3.69 fold spurt over two-week average daily volume of 11733 shares. The stock rose 0.59% to Rs.1,344.75. Volumes stood at 15468 shares in the last session.Powered by Capital Market - Live

On consolidated basis, the firm's net profit declined 15.74% to Rs 163.53 crore on 2.36% to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24. Profit before tax (PBT) stood at Rs 256.78 crore, down 11.42% as compared with Rs 289.89 crore in second quarter of FY24. For Q2 of FY25, EBITDA was Rs 296.1 crore, registering de-growth of 8%. EBITDA margin reduced from 21% to 23% during the quarter. Revenue from US market stood at Rs 754.7 crore (up 3% YoY), revenue Europe was at Rs 245.9 crore (down 1% YoY), Canada, Australia and New Zealand stood at Rs 51.5 crore (up 45% YoY) while revenue from India was at Rs 87.4 crore and Rest of the world was at Rs 266.3 crore during the period under review. Total capex incurred during the quarter was Rs 103.7 crore. R&D expenses stood at Rs 49.3 crore in Q2 of FY25, (4.6% of revenue). Cenexi's gross profit shed 15% YoY to Rs 234.7 crore and revenue from operations decreased 5% YoY to Rs 339.9 crore during the quarter. On outlook front, the company said that despite the near-term headwinds, it continued to strive to achieve short-term outlook: a positive EBITDA for Q4 of FY25. It maintains goal of a positive EBITDA for the next fiscal year, driven by an increase in revenue above the '200 million threshold. Srinivas Sadu, executive chairman and CEO of Gland Pharma, said, 'We had a good first half of 2025 and are on course to achieve our outcomes for the full year. This quarter, we reported Rs 14,058 million in revenue and Rs 2,961 million in EBITDA, representing a 21% EBITDA margin. Although our overall EBITDA margin was affected by Cenexi, our base business maintained a steady 34% EBITDA margin. Our core regulated markets, particularly the United States, continue to perform well. Our overall performance is in line with expectations. Looking ahead, we remain focused on our strategic priorities, which include entering new markets and building a solid foundation for future growth.' Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.Powered by Capital Market - Live

Net profit of Gland Pharma declined 15.74% to Rs 163.53 crore in the quarter ended September 2024 as against Rs 194.08 crore during the previous quarter ended September 2023. Sales rose 2.36% to Rs 1405.83 crore in the quarter ended September 2024 as against Rs 1373.42 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1405.831373.42 2 OPM %21.1323.60 - PBDT350.60371.19 -6 PBT256.78289.89 -11 NP163.53194.08 -16 Powered by Capital Market - Live

Gland Pharma will hold a meeting of the Board of Directors of the Company on 4 November 2024.Powered by Capital Market - Live

Gland Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1809, down 1.76% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.06% on the day, quoting at 25392.05. The Sensex is at 83172.83, up 0.27%.Gland Pharma Ltd has lost around 6.26% in last one month.Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has increased around 2.13% in last one month and is currently quoting at 23025.2, down 0.76% on the day. The volume in the stock stood at 77964 shares today, compared to the daily average of 3.85 lakh shares in last one month.The PE of the stock is 28.14 based on TTM earnings ending June 24.Powered by Capital Market - Live